Cambridge, UK-based Constellation Pharmaceuticals has appointed Adrian Senderowicz as its senior vice president and chief medical officer.
Senderowicz has over 20 years’ experience in the life sciences sector, with his most recent role seeing him sit on Puma Biotechnology’s board of directors.
Prior to his time at Puma, Senderowicz held several roles for the life sciences sector including team leader at the US Food and Drug Administration (FDA), vice president, global regulatory oncology for Sanofi and medical director and senior director, oncology for AstraZeneca.
He said: “Constellation Pharmaceuticals is poised to deliver on the promise of its pioneering research in epigenetics by developing therapies that have the potential to address significant medical needs in difficult-to-treat tumours.
“The company has established a clear path to registration for its two lead clinical development programmes – CPI-1205 in solid tumours and CPI-0610 in a molecularly defined and prospectively selected patient population.
“I look forward to working with the entire team to help ensure the rapid advancement of these potential new medicines for cancer patients.”
Senderowicz has also held roles of increasing responsibility at Ignyta, Tokai Pharmaceuticals and Cerulean Pharma, where he helped secure fast-track designation for the company’s lead clinical development programme in two indications.
Jigar Raythatha, president and chief executive officer at Constellation Pharmaceuticals, said: “Adrian has deep expertise translating early scientific research into meaningful clinical outcomes, and possesses the vision, experience and leadership skills required to realise the company’s full potential during this next phase of its evolution.
“His background in drug development and the regulatory process will be instrumental as we advance our two lead clinical programmes toward registration.”
In addition to Senderowicz’s appointment, the group is bolstering its effort by aligning its management team with near-and long-term research and development priorities.
Patrick Trojer has been promoted to senior vice president of the EZH2 franchise and head of translational services, and will be responsible for integrating translational research, clinical development and pre-commercial activities across CPI-1205 and the company’s next generation of PRC2 medicines.
Robert Sims has also been promoted to senior vice president of research and both Sims and Trojer will work with Senderowicz to advance its two on-going clinical development programmes and novel R&D programmes.
Furthermore, Brenda Sousa has been promoted to senior vice president of human resources and operations and will continue to focus on talent acquisition and development, as well as operations to ensure the company is well positioned to achieve its goals.